Pharmacoepidemiology of antagonist receptors of the angiotensin (ARA) II in the treatment of essential hypertension. Mexico

Abstract

Epidemiology of hypertension: Epidemiology of hypertension globally, it is reported that the prevalence of hypertension in adult population is between 20-27%. Pharmacotherapy: ARA II exert their action by blocking AT1 receptors Angiotensin II in a specific and highly selective and act by inhibiting the adverse effects angiotesin II classic. Thus, antagonize the action of angiotensin II produced by any means and do not act on enzymatic degradation of kinins, so do not condition an increase in blood levels. In addition to the ATI receptor blockade ARA II allow the circulating Angiotensin II may be linked to the AT2 receptor, which can add an additional potentially beneficial. Studies of morbidity and mortality in hypertension with ARA II: The efficacy of ARA II for lowering blood pressure is well established for several years, both in mild hypertension and moderate or severe and multiple studies comparing these drugs have shown similar antihypertensive efficacy to that of IECA inhibitors, calcium antagonists or beta-blockers. Therefore, given similar antihypertensive efficacy and better tolerability profile the ARA II may be considered a very useful drug family in the current treatment of hypertension. Conclusions: The conclusion of the authors of several studies is that IECA inhibitors and ARA II have similar antihypertensive effectiveness and IECA inhibitors, poorer tolerability.